Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) has appointed David A. Spellman as the new Senior Vice President, Chief Financial Officer, and Treasurer, effective June 29, 2020. Spellman brings over 20 years of financial experience from companies like Intarcia and Vertex Pharmaceuticals. His role will be crucial as Akebia advances vadadustat, an investigational therapy in Phase 3 for treating anemia due to chronic kidney disease (CKD). Former CFO Jason A. Amello transitions out after 7 years to pursue other interests, ensuring a smooth handover during the transition.